Skip to content
Search

Latest Stories

Oxford-AstraZeneca Covid vaccine challenged in High Court

The firm supplied 3 billion doses of the vaccine to more than 180 countries and said that an independent study had found it had been responsible for saving 6 million lives

Oxford-AstraZeneca Covid vaccine challenged in High Court

The Oxford-AstraZeneca Covid-19 vaccine, recognised as Vaxzevria in Europe and licensed as Covishield in India, is confronting a legal challenge in the High Court in London, a media report said on Thursday (9).

According to ‘The Daily Telegraph', UK-based pharmaceutical giant AstraZeneca could face a number of further claims based on the outcome of test cases around the condition identified by specialists as Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT), believed to be related to the side effects of the Covid jab.


AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world “consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects".

"The fact of this legal battle poses a fundamental question: in circumstances where individuals are seriously injured or die because of a vaccination recommended by the government – should the state provide access to adequate compensation, or should the bereaved and injured be required to fight for compensation in the courts against the vaccine producer,” states Sarah Moore, a partner at the law firm Hausfeld, which is bringing the case on behalf of the Covid vaccine claimants.

Among the claimants for damages is Indian-origin Anish Tailor, whose wife – 35-year-old Alpa Tailor – died in April 2021, just under a month after having the vaccine. An inquest in September 2021 is said to have determined she died from blood clots and bleeding on the brain caused by VITT.

The test claim is being brought by Jamie Scott, a father-of-two who suffered brain injury after receiving the jab in April 2021, who is also part of the “Vaccine Injured and Bereaved vs AstraZeneca – VITT Litigation” CrowdJustice group, which has raised over GBP 8,000 of its GBP 10,000 target to support its legal “fighting fund”.

In its statement, AstraZeneca said, "We do not comment on ongoing litigation matters."

However, it added, "Patient safety is our highest priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines. Our sympathy goes out to anyone who has lost loved ones or reported health problems.

“From the body of evidence in clinical trials and real-world data, Vaxzevria has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects.”

The firm also pointed out that it supplied 3 billion doses of the vaccine to more than 180 countries and that an independent study had found it had been responsible for saving 6 million lives.

Meanwhile, a UK-based Indian-origin consultant cardiologist who has been campaigning for greater scrutiny of the Covid vaccines urged the Indian government to conduct its own investigation.

"After publishing research last year making the case for the suspension of the Covid mRNA vaccine over its safety, I was shocked to learn that as far as cardiovascular effects were concerned, the Covishield vaccine was even worse for its short-term cardiovascular harms,” said Dr Aseem Malhotra.

"Given this landmark case on AstraZeneca's vaccine in the UK, in my view, it's clear that neither of these vaccines should have been administered to a single human in the first place and certainly not without informed consent. I call on prime minister (Narendra) Modi to investigate,” he said.

(PTI)

More For You

Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
From silence to spotlight: How Ella D’Verma turned her truth into power

In a world still catching up with the truths of trans identity

Instagram / elladverma

From silence to spotlight: How Ella D’Verma turned her truth into power

AS Pride Month sweeps across the world in a blaze of colour, protest and celebration, one Indian voice continues to rise with unwavering authenticity. Ella D’Verma is reshaping narratives as a transgender model, fearless LGBTQ+ advocate and digital content creator with a powerful global following.

In a world still catching up with the truths of trans identity, her visibility has become vital – the embodiment of pride in action. In this exclusive conversation with Eastern Eye, she speaks about her journey, the importance of visibility, self-expression, navigating the fashion industry as a trans model, representation, and her vision for the future.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less
Asian representation Parkinson’s awareness

Organisations like Parkinson’s UK are so vital.

Instagram/ itsmitamistry

Joining the movement: Championing Asian representation and Parkinson’s awareness through sport

Mita Mistry

I recently joined the incredible team at the Asian Sports Foundation. It is an honour to work alongside passionate individuals such as Shazia Ali, Harleen Kaur and Angus Martin. Since it was founded by Jug Johal, the Asian Sports Foundation has worked to transform inactivity into active living, promoting better wellbeing and greater representation of Asian communities in sport and physical activity.

This is a cause close to my heart. The undeniable power of sport and movement to improve both physical and mental health cannot be overstated. It is a message I have consistently championed, alongside a commitment to equity and inclusion, which is why I am so excited to contribute to a charity that truly embodies this ethos.

Keep ReadingShow less